| Trial name or title |
FOLFOXIRI With or Without Cetuximab as First‐line Treatment of Patients With Non‐resectable Liver‐Only Metastatic Colorectal Cancer (FOCULM) |
| Methods |
Phase II randomised controlled trial |
| Participants |
138 people with KRAS/NRAS WT mCRC |
| Interventions |
Arm A: the combination of FOLFOXIRI and cetuximab. Arm B: FOLFOXIRI alone |
| Outcomes |
Primary outcome: percentage of participants with curative liver treatment (complete resection/ablation) following protocol treatment. Secondary outcomes: reported adverse events, response rate, PFS, time to recurrence, quality of life (EORTC QLQ‐C30) |
| Starting date |
February 2014 |
| Contact information |
Yanhong Deng, MD 008613925106525 13925106525@163.com |
| Notes |
|
